Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Nice Systems, Protalix, Ratio Oil, Teva: Israeli Equity Preview

May 4 (Bloomberg) -- The following stocks may rise or fall in Israeli markets. Stock symbols are in parentheses after the company names and prices are from the last close unless otherwise stated.

The TA-25 Index lost 0.8 percent to 1,281.91 in Tel Aviv.

Nice Systems Ltd. (NICE IT): The maker of digital-recording surveillance products is scheduled to report first-quarter earnings. Analysts expect net income of 23 cents a share, according to the median estimate of seven analysts on Bloomberg. Nice dropped 1.6 percent to 122.70 shekels.

Protalix BioTherapeutics Ltd. (PLX IT): David Aviezer, chief executive officer of the biotechnology company, is scheduled to present at the Bio-Manguinhos International Symposium on Immunobiologicals in Brazil. Protalix dropped 2.9 percent to 22.29 shekels.

Ratio Oil Exploration 1992 LP (RATIL IT): The oil and gas explorer said it raised 258 million shekels ($76 million) from its offering of partnership units. Ratio declined 2.4 percent to 0.441 shekel.

Teva Pharmaceutical Industries Ltd. (TEVA IT): The U.S. Food and Drug Administration warned the world’s largest maker of generic drugs that a Jerusalem plant distributed drugs without adequate testing and that the company must fix the issues or face approval delays and a ban on imports. Teva fell 1.4 percent to 158.90 shekels.

To contact the reporter on this story: Sharon Wrobel in Tel Aviv at swrobel4@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.